2022-08-17
French B et al. . JAMA. 2022 Aug 4. doi: 10.1001/jama.2022.
在2020年12月1日的《美国医学会杂志》上,Self等人报道了一项随机临床试验,试验评估了羟氯喹治疗与安慰剂相比是否改善了COVID-19住院成人的临床结局。主要转归是患者随机分组后14天的临床状态,用顺序7类量表进行评估,从最差(“死亡”)到最好(“出院并能进行正常活动”)。
羟氯喹组和安慰剂组在第 14 天的序数结果量表上的临床状态没有显着差异(中位 [IQR] 评分,6 [4-7] vs 6 [4-7];aOR,1.02 [95% CI,0.73至 1.42])。12 项次要结局在各组之间均无显着差异。随机分组后 28 天,羟氯喹组 241 名患者中有 25 名(10.4%)和安慰剂组 236 名患者中有 25 名(10.6%)死亡(绝对差异,-0.2% [95% CI,-5.7% 至 5.3% ];aOR,1.07 [95% CI,0.54 至 2.09])
在因 COVID-19 住院的呼吸系统疾病成人中,与安慰剂相比,羟氯喹治疗在第 14 天并未显着改善临床状态。这些发现不支持在住院成人中使用羟氯喹治疗 COVID-19
Abstract
In the December 1, 2020, issue of JAMA, Self et al1 reported a randomized clinical trial that evaluated whether treatment with hydroxychloroquine improved clinical outcomes of adults hospitalized with COVID-19 compared with placebo. The primary outcome was the patient’s clinical status 14 days after randomization, assessed with an ordinal 7-category scale ranging from worst (“death”) to the best (“discharged from the hospital and able to perform normal activities”). The term “ordinal” is applied to an outcome measure for which its mutually exclusive categories can be ordered by their clinical preference. The primary outcome was analyzed with a multivariable ordinal logistic regression model, which is a regression model for an ordinal dependent variable. The authors found that there was not a statistically significant difference between the hydroxychloroquine and placebo groups in clinical status 14 days after randomization.
文章连接:
https://jamanetwork.com/journals/jama/fullarticle/2795186
百度浏览 来源 : 医微客
版权声明:本网站所有注明来源“医微客”的文字、图片和音视频资料,版权均属于医微客所有,非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源:”医微客”。本网所有转载文章系出于传递更多信息之目的,且明确注明来源和作者,转载仅作观点分享,版权归原作者所有。不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。 本站拥有对此声明的最终解释权。
发表评论
注册或登后即可发表评论
登录注册
全部评论(0)